TIKOMED Successfully Closed Fundraising of 8 Million Euros

TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB-program and the IBsolvMIR® program.

TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILBprogram) and an infusion product for improving outcomes in cell therapies (IBsolvMIR® program).

“I’m delighted that we have successfully completed our latest fundraising, which demonstrates both the level of interest and trust in our clinical program from investors,” said Anders Kristensson, CEO of TIKOMED.

Source: TIKOMED

Share:


Categories: Pharmaceuticals and Biotech

Tags: Amyotrophic Lateral Sclerosis, Cell therapy, Clinical development program, Fundraising, IBsolvMIR, ILB, Islet Cell transplantation, TIKOMED


About TIKOMED AB

View Website or Media Room

TIKOMED, a specialty pharma company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion product for improving outcomes in cell therapies (IBSOLVMIR® program).